DECLARATIONS
All procedures were carried out in accordance with guidelines set forth by the Declaration of Helsinki.
Competing interests:Ownership: YS – EpiDestiny. Income: none. Research support: none. Intellectual property: YS - patents around tetrahydrouridine, decitabine and 5-azacytidine (US 9,259,469 B2; US 9,265,785 B2; US 9,895,391 B2) and cancer differentiation therapy (US 9,926,316 B2).
Acknowledgements and Funding: We thank Edward P. Evans Foundation, the HENRY & MARILYN TAUB FOUNDATION, and grants to JPM: R01HL118281, R01HL123904, R01HL132071, R35HL135795; the American-Italian Cancer Foundation Post-Doctoral Research Fellowship (to CG); grants to YS: National Heart, Lung and Blood Institute PO1 HL146372, National Cancer Institute P30 CA043703, National Cancer Institute RO1 CA204373.
Authors’ Contributions: M.Z., C.G. and Y.S. wrote the manuscript. S.P., H.A. and J.P.M kindly reviewed the clinical data and helped edited the manuscript. All authors participated in critical review of the final paper and approved the submitted version.